MATTAWAN, Mich.--(BUSINESS WIRE)--MPI Research, the largest single-site preclinical contract research organization worldwide, is pleased to announce that Roger N. Hayes, PhD, will be joining the company as Vice President and General Manager, Laboratory Sciences, effective November 14, 2011.
Dr. Hayes has held numerous leadership positions in the global life sciences industry and academia, leading teams in the development of state-of-the-art bioanalytical and analytical techniques, including mass spectrometry, chromatography, and automation in bringing medical and chemical products to market. For nearly two decades, he led strategic and research initiatives for large pharmaceutical companies that included both GLP and non-GLP preclinical studies as well as clinical trials. At Merck Research Laboratories (2000-2010), Dr. Hayes directed the regulated bioanalysis group in support of preclinical and clinical safety trials and also advanced efficiencies for method development and validation. At Parke-Davis Pharmaceuticals (1993-2000), he managed the instrumentation support department, headed the Bioanalytical Groups for both safety and discovery research, and did cutting-edge work as the leader of the Drug Metabolism Mass Spectrometry Group. Prior to that, Dr. Hayes spent several years at Procter and Gamble, where he developed new analytical technology and processes. His career is rooted in academia, beginning at the University of Adelaide in Australia, where he received his PhD and performed innovative research in gas phase ion chemistry. From there, he went to the University of Nebraska-Lincoln, where he served as an Assistant Director/Assistant Research Professor and continued his ground-breaking research, with an emphasis on advancements in the use of mass spectrometry. Most recently (2011), he served as President, Bioanalytical Operations, at Cetero Research where he focused on establishing overall corporate direction for bioanalytical and analytical services. Dr. Hayes has published extensively and has taught numerous aspects of LC/MS method development.
According to MPI Research President and COO, Tim Derrington, “Dr. Hayes is a recognized expert in the field of bioanalytical and analytical testing and we are honored to have him join our leadership team. Under his direction, MPI Research will continue to expand our bioanalytical, immunology, analytical, and biomarker services. Our established scientific team is eager to work with Dr. Hayes as we partner with our pharmaceutical, biotech, chemical, and animal health Sponsors in bringing their products to market.”
Please join us in welcoming Dr. Hayes to MPI Research!
MPI Research, with global headquarters in Mattawan, Michigan, provides safety evaluation, discovery, bioanalytical, and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world. Learn more about how we can exceed your expectations at www.mpiresearch.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50068079&lang=en